Overview. Cannabis stability is more complex than monitoring potency alone. Cannabinoids can oxidise or decarboxylate, terpenes can evaporate, moisture can migrate, microbiological quality can change and packaging can interact with the product. Stability studies should therefore be designed around the specific degradation pathways of the dosage form.
Stability objectives
A stability programme supports shelf life, storage conditions, packaging selection, transport controls and in-use instructions. The protocol should define batches, strengths, pack types, storage conditions, pull points, tests and acceptance criteria.
Dried flower
Flower stability should consider cannabinoid profile, water activity, moisture content, microbiology, appearance, odour and volatile loss. Moisture exchange through the package may be as important as chemical degradation. Whole-flower and milled material may behave differently.
Oils and extracts
Oil formulations may be vulnerable to oxidation, precipitation, adsorption to packaging and light exposure. Extracts may show changes in cannabinoid distribution, residual solvent and impurity profile. Antioxidants, headspace and container material should be assessed.
Capsules and sprays
Capsules require evaluation of shell-fill interaction, leakage, content uniformity and dissolution or disintegration. Sprays require delivered-dose uniformity, priming and in-use performance in addition to chemical stability.
Storage conditions and chamber control
Long-term, accelerated and, where relevant, intermediate conditions should reflect target markets. Stability chambers should be qualified, mapped and continuously monitored. Excursions must be assessed for both duration and magnitude.
Trend evaluation and shelf-life assignment
A passing result at every time point does not automatically prove a robust shelf life. Trends should be reviewed for slope, variability and likely future performance. Shelf-life specifications may differ from release specifications where justified.
Photostability and in-use studies
Light-sensitive products may require ICH Q1B-style studies. Multi-dose oils and sprays require in-use studies that simulate repeated opening, dosing, orientation and storage.
Practical reference table
| Product | Likely stability risk | Useful test |
|---|---|---|
| Dried flower | Moisture loss or gain | Water activity and moisture content |
| Dried flower | THC oxidation to CBN | Cannabinoid profile |
| Oil | Oxidation or precipitation | Assay, impurities and appearance |
| Capsule | Shell-fill interaction | Dissolution and leakage |
| Oromucosal spray | Evaporation or dose drift | Delivered-dose uniformity |
| Extract | Residual solvent or impurity change | Assay and impurity profile |
Control and decision path
Frequently asked questions
How many batches are needed for stability studies?
The number depends on development stage and regulatory strategy, but the programme should represent process and packaging variability.
Does flower require microbiological stability testing?
Yes where microbiological quality may change during storage.
Can accelerated stability replace long-term data?
No. Accelerated studies support understanding and may support extrapolation, but long-term data remain fundamental.
What is an in-use stability study?
It evaluates the product after opening and during realistic repeated patient use.
Can one packaging configuration support another?
Only with a justified bracketing or comparability rationale.
Primary references and guidance
- ICH Q1A(R2), Stability Testing
- ICH Q1B, Photostability Testing
- ICH Q1E, Evaluation of Stability Data
- EU GMP Part I, Chapter 6
- European Pharmacopoeia, Cannabis flower monograph
- EMA stability guidelines
- WHO stability guidance
- EU GMP Annex 15
Confirm the current effective revision and national applicability before operational or regulatory use.